bromfenac ophthalmic solution

Changing the game in treatment of acute pseudophakic CMEJoshua Mali, MD, provides clinical evidence and recommendations for pseudophakic CME and represents a new formal standard to first-line management.
Pain-preventing NSAID welcomed by patients and cliniciansA new 0.075% formulation of bromfenac ophthalmic solution (BromSite, Sun Pharma) could provide relief from pain and inflammation associated with cataract surgery.
FDA approves generic postop inflammation drugThe FDA has granted final approval for Hi-Tech Pharmacal Co. Inc.’s Abbreviated New Drug Application for its bromfenac ophthalmic solution, 0.09% (once-a-day).